NCT07431086Active, not recruitingPhase 2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, Tolerability, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity in the US
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity. The study will test how safe and effective the study drug works compared to placebo in people who are overweight or obese but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much the study drug is in the blood at different times * How well the study drug works * If the body makes antibodies to the study drug as this may cause the study drug to not work as well
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- First submitted
- 18 Feb 2026
- Start date
- 16 Mar 2026
- Primary completion date
- 13 Nov 2026
- Lead sponsor
- Regeneron Pharmaceuticals
- Diseases
- Obesity
- NCT number
- NCT07431086
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 120
- From 16 Mar 2026 to the primary completion date, 13 Nov 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Change in body weight \>5 kg within approximately 3 months before screening as described in the protocol
- Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions, prior to randomization or planned during the study period
Other illness
- History of Type 1 or Type 2 diabetes
- History of any of the following conditions: acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones or has a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years as described in the protocol
- Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
Who the study is looking for
- Body mass index ≥27.0 kg/m\^2 to \<45.0 kg/m\^2 at screening
- Demonstrates ability and willingness to comply with the study protocol, including attending all scheduled visits, adhering to the prescribed treatment regimen, and completing all required assessment
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Flourish Research - San Antonio Medical Trials Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
| Diablo Clinical Research - Flourish Research Coordinator of this site? Confirm its status | Walnut Creek | United States | Unknown status |
| Clinical Site Partners, LLC dba Flourish Research Coordinator of this site? Confirm its status | Winter Park | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.